Table 1

Patient demographics, chronic asthma factors, acute asthma presentation and emergency department (ED) course for asthma exacerbation, according to the number of ED visits in the 1-year period

1 ED visit2 ED visits≥3 ED visits
Variables*(n=784)(n=117)(n=101)p Value
Age (years), median (IQR)34 (26–43)34 (25–42)37 (27–43)0.45
Male sex43 (40–47)41 (32–50)39 (29–49)0.64
Current smoker42 (39–46)32 (24–42)49 (38–59)0.045
Chronic asthma factors
 History of oral corticosteroid use for asthma35 (31–40)75 (64–84)84 (75–91)<0.001
 History of hospital admission for asthma23 (20–27)50 (39–61)66 (55–75)<0.001
 History of intubation for asthma1 (1–3)1 (0–7)8 (3–16)<0.001
 History of hospital admission for asthma in the past year2 (1–3)19 (12–28)34 (25–45)<0.001
 Current use of inhaled corticosteroids23 (20–26)45 (36–55)63 (53–72)<0.001
 Current use of oral xanthines10 (8–12)12 (7–20)26 (18–36)<0.001
 Current use of leukotriene modifiers8 (6–10)16 (10–25)29 (21–39)<0.001
Acute asthma presentation
Duration of symptoms
 <4 h before ED arrival16 (14–19)13 (7–20)21 (13–31)0.08
 4–23 h43 (40–47)49 (39–58)53 (42–63)
 1–7 days34 (31–38)36 (27–46)22 (14–32)
 >7 days7 (5–9)3 (1–8)4 (1–10)
ED course
 Initial respiratory rate (breath/min), mean (SD)22±621±624±60.07
 Initial oxygen saturation (%), mean (SD)95±395±495±40.12
 Initial peak flow† (L/min), mean (SD)214±103254±63170±570.21
 Number of inhaled β-agonists in first hour, median (IQR)1 (1–2)1 (1–2)1 (1–2)0.33
 Number of inhaled β-agonists over ED stay, median (IQR)1 (1–2)1 (1–2)2 (1–2)0.17
 Received systemic corticosteroid treatment41 (37–44)44 (34–53)62 (52–72)<0.001
ED disposition0.62
 Sent home89 (86–91)86 (79–92)89 (81–94)
 Hospital admission11 (9–13)12 (7–19)11 (6–19)
 Other (eg, left against medical advice)1 (0–1)2 (0–6)0
Sent home with systemic corticosteroids35 (32–39)29 (20–39)32 (23–43)0.42
  • *Data were expressed as % (95% CI) unless otherwise specified.

  • †Analysed for 56 patients (6%) with initial peak flow available.